APA (7th ed.) Citation

Shields, R. K. (2018). Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections [Clinical Therapeutics]. The American Society for Microbiology (ASM).

Chicago Style (17th ed.) Citation

Shields, R. K. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance Among Patients with Carbapenem-Resistant Enterobacteriaceae Infections [Clinical Therapeutics]. The American Society for Microbiology (ASM), 2018.

MLA (9th ed.) Citation

Shields, R. K. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance Among Patients with Carbapenem-Resistant Enterobacteriaceae Infections [Clinical Therapeutics]. The American Society for Microbiology (ASM), 2018.